DMAAU
Drugs Made In America Acquisition Corp.
NASDAQ · Financial Services · Financial - Conglomerates · US
$10.82
+0.28%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+1.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Feb 18, 2025 | Drugs Made In America Acquisition LLC · 10 percent owner | Purchase | 30,000 | $0.00 |
| Feb 18, 2025 | Stockwell Lynn · director, 10 percent owner, officer: CEO and Exe. Chair of Board | Purchase | 30,000 | $0.00 |
| Feb 4, 2025 | Drugs Made In America Acquisition LLC · 10 percent owner | Purchase | 400,000 | $0.00 |
| Feb 4, 2025 | Drugs Made In America Acquisition LLC · 10 percent owner | Sale | 5,698,363 | $1.50 |
| Feb 4, 2025 | Stockwell Lynn · director, 10 percent owner, officer: CEO and Executive COB | Sale | 5,698,363 | $1.50 |
| Feb 4, 2025 | Stockwell Lynn · director, 10 percent owner, officer: CEO and Executive COB | Purchase | 400,000 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 0Increased 2Reduced 2Sold out 0
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Clear Street Group Inc. | Increased | 10,005 | Aug 12, 2026 |
| CLEAR STREET GROUP INC. | Reduced | 10,000 | May 15, 2026 |
| UBS Group AG | Increased | 1,525 | Aug 13, 2026 |
| UBS GROUP AG | Reduced | 1,521 | May 5, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Feb 18, 2025